We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

126 hedge funds and large institutions have $324M invested in Ventyx Biosciences in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more capital invested

Capital invested by funds: $112M → $324M (+$213M)

23.08% more ownership

Funds ownership: 76.5%99.58% (+23%)

19% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $1.07M

16% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 37

4% more funds holding

Funds holding: 121126 (+5)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

15% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 39

Holders
126
Holders Change
+5
Holders Change %
+4.13%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
43
Increased
33
Reduced
39
Closed
37
Calls
$1.27M
Puts
$1.07M
Net Calls
+$205K
Net Calls Change
+$2.73M
Name Holding Trade Value Shares
Change
Change in
Stake
HighTower Advisors
51
HighTower Advisors
Illinois
$537K -$84.9K -18,557 -16%
Two Sigma Advisers
52
Two Sigma Advisers
New York
$486K -$4.67M -1,020,700 -92%
Two Sigma Investments
53
Two Sigma Investments
New York
$482K -$4.76M -1,040,938 -92%
Mirae Asset Global Investments
54
Mirae Asset Global Investments
South Korea
$404K +$60.2K +13,169 New
RhumbLine Advisers
55
RhumbLine Advisers
Massachusetts
$360K -$55K -12,036 -16%
Group One Trading
56
Group One Trading
Illinois
$349K -$1.19M -259,581 -80%
JGC
57
J. Goldman & Co
New York
$342K +$285K +62,262 New
NYLIM
58
New York Life Investment Management
New York
$335K +$278K +60,850 New
UBS Group
59
UBS Group
Switzerland
$327K +$272K +59,519 New
CSS
60
Cubist Systematic Strategies
Connecticut
$309K -$1.26M -274,464 -83%
AllianceBernstein
61
AllianceBernstein
Tennessee
$275K -$27.7K -6,060 -11%
T. Rowe Price Associates
62
T. Rowe Price Associates
Maryland
$265K -$710K -155,291 -76%
ECM
63
ExodusPoint Capital Management
New York
$247K +$205K +44,911 New
Squarepoint
64
Squarepoint
New York
$209K -$871K -190,474 -83%
XT
65
XTX Topco
Cayman Islands
$207K -$1M -218,998 -85%
PCM
66
Prelude Capital Management
New York
$206K +$43K +9,400 +34%
Brown Advisory
67
Brown Advisory
Maryland
$204K -$21K -4,600 -11%
FRM
68
Fox Run Management
Connecticut
$184K +$153K +33,490 New
Barclays
69
Barclays
United Kingdom
$182K -$184K -40,258 -55%
WC
70
Wexford Capital
Florida
$165K +$137K +30,000 New
BFG
71
Bleakley Financial Group
New Jersey
$162K -$14.5K -3,177 -10%
SW
72
Simplicity Wealth
New Jersey
$162K +$134K +29,405 New
BC
73
Birchview Capital
Vermont
$158K
MIM
74
MetLife Investment Management
New Jersey
$138K +$115K +25,056 New
Deutsche Bank
75
Deutsche Bank
Germany
$127K +$67.9K +14,846 +180%

VTYX Hedge Fund Activity: Q1 2024 in Review

126 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q1 2024, worth a combined $324M — up 191% from $112M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new VTYX positions and 37 closed out — a net gain of 6 holders — while 33 added to existing stakes and 39 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $16.2M. The largest seller was Morgan Stanley, cutting an estimated $11.4M.

  • 126 institutional investors held Ventyx Biosciences (VTYX) as of Q1 2024, up from 121 in Q4 2023.
  • Funds reported $324M of Ventyx Biosciences stock for Q1 2024, up 191% quarter-over-quarter.
  • 43 funds opened new Ventyx Biosciences positions in Q1 2024 and 37 closed out, a net change of +6 holders.
  • The largest Ventyx Biosciences buyer in Q1 2024 was Deerfield Management, an estimated $16.2M added.
  • The largest Ventyx Biosciences seller in Q1 2024 was Morgan Stanley, an estimated $11.4M sold.

Based on aggregated 13F filings for Q1 2024.